MedTrace Logo

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

NCT00024414 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-07-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

DRUG

DHA-paclitaxel

Sponsors & Collaborators

  • Theradex

    lead INDUSTRY

Principal Investigators

  • Michael A. Carducci, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00024414 on ClinicalTrials.gov